Skip to content
Research archive

Research Articles

Randomized Controlled Trial

Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study.

Continuous Cefuroxime Infusion Achieves Superior Tissue Exposure Over Bolus Dosing in Oral Cancer Surgery — Both bolus and continuous infusion regimens of 4500 mg daily cefuroxime met the minimum pharmacodynamic target of 50% time above MIC across all sampled tissue compartments, but continuous infusion achieved 100% time above MIC in every compartment at both MIC thresholds, compared to 79–98% with bolus dosing.

Mar 4, 2026 · J Antimicrob Chemother · Oncology
60
Clinical Trial

Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.

Quizartinib Prolongs Survival in FLT3-ITD AML Without Worsening Quality of Life — In a phase 3 randomised trial of 509 patients with newly diagnosed FLT3-ITD-positive acute myeloid leukaemia, adding quizartinib to standard chemotherapy produced no clinically meaningful difference in patient-reported quality of life compared with placebo (treatment difference in global health status score: −2.0, 95% CI −4.8 to 0.7).

2026 · Lancet Haematol · Oncology
72
Randomized Controlled Trial

Effect of Nurse-led Intervention on Shoulder Dysfunction among Breast Cancer Patients Undergoing Modified Radical Mastectomy (MRM), South India: A Randomized Controlled Trial.

Nurse-Led Exercise Intervention Sharply Reduces Shoulder Dysfunction After Mastectomy — A randomized controlled trial of 320 breast cancer patients found that those receiving a structured nurse-led rehabilitation intervention had dramatically lower disability scores at 12 months — a median DASH score of 5.17 compared to 24.14 in the control group (p < 0.001).

Mar 1, 2026 · Asian Pac J Cancer Prev · Oncology
72
Randomized Controlled Trial

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

DVRd Plus DR Maintenance Shows Superior Progression-Free Survival Over Current Transplant-Eligible NDMM Standards — In an indirect treatment comparison using individual patient-level data, the four-drug regimen daratumumab, bortezomib, lenalidomide, and dexamethasone followed by daratumumab-lenalidomide maintenance reduced the risk of disease progression or death by approximately 61% compared with daratumumab-VTd followed by lenalidomide maintenance (HR 0.39, 95% CI 0.26–0.59).

Feb 17, 2026 · J Med Econ · Immunology
60
Clinical Trial

Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.

Pfizer's rAAV9 Mini-Dystrophin Gene Therapy Fails Primary Efficacy Endpoint in Duchenne Trial — At 52 weeks, fordadistrogene movaparvovec produced no meaningful improvement over placebo in motor function scores among young boys with Duchenne muscular dystrophy, with the treatment and placebo groups showing nearly identical changes from baseline (difference of 0.09 points on the NSAA scale; 95% CI −1.46 to 1.64; p=0.91).

2026 · Lancet Neurol · Infectious Diseases
83
Clinical Trial

Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China.

Novel Three-Component DTcP Vaccine Meets Non-Inferiority and Superiority Thresholds Against Licensed Comparator — A phase III randomised trial in China found that both primary schedules of the novel genetically engineered three-component acellular pertussis vaccine (DTcP) achieved non-inferior safety profiles and superior or non-inferior immunogenicity against all pertussis antigens compared with the licensed DTaP-IPV-Hib (Pentaxim) control.

Feb 16, 2026 · Emerg Microbes Infect · Infectious Diseases
66
Clinical Trial

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Lenvatinib Plus Pembrolizumab Doubles Five-Year Survival Over Chemotherapy in Advanced Endometrial Cancer — At five years of follow-up, nearly 20% of all-comer patients with previously treated advanced endometrial cancer remained alive on lenvatinib plus pembrolizumab compared with 7.7% on chemotherapy, representing a more than twofold survival advantage that was sustained across both mismatch repair subgroups.

Feb 19, 2026 · J Immunother Cancer · Oncology
76
Randomized Controlled Trial

Sex- and Age-Stratified Outcomes of Colonoscopy Versus Faecal Immunochemical Testing: Post-Analysis of the COLONPREV Study.

FIT and Colonoscopy Reduce CRC Mortality Equally Across Sex and Age Groups — A post-hoc stratified analysis of the COLONPREV randomised trial found that reductions in colorectal cancer-related mortality and incidence were consistent across sex and age subgroups for both faecal immunochemical testing and colonoscopy screening, though men and older participants retained persistently higher baseline cancer risk that neither strategy fully resolved.

2026 · United European Gastroenterol J · Oncology
72
Randomized Controlled Trial

Efficacy of a sexual quality of life intervention for couples facing metastatic breast cancer: Results of a randomized controlled trial.

Couple-Based Video Intervention Improves Sexual Quality of Life in Metastatic Breast Cancer — A randomized controlled trial found that a four-session videoconference intervention for couples affected by metastatic breast cancer produced statistically significant and durable improvements in patients' sexual function, desire, distress, and satisfaction compared to an informational booklet, with benefits persisting at six-month follow-up.

Mar 1, 2026 · Cancer · Oncology
75
Randomized Controlled Trial

Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Incidence in Women Aged 40–49 — Over a median follow-up exceeding 11 years, adding ultrasonography to mammography screening was associated with about a 17% lower risk of advanced breast cancer in women aged 40–49 compared with mammography alone (HR 0.83, 95.6% CI 0.70–0.98).

Feb 21, 2026 · Lancet · Oncology
66